28 May 2021 in European Respiratory Journal
Thymic stromal lymphopoietin (TSLP), an epithelial upstream cytokine, initiates production of type-2 (T2) cytokines with eosinophilia and possibly airway hyperresponsiveness (AHR) in asthma.This study aimed to determine whether tezepelumab (a human monoclonal antibody targeting TSLP) decreases AHR and airway inflammation in patients with symptomatic asthma on maintenance treatment with inhaled corticosteroids. In this double-blind, placebo-controlled randomised trial adult patients with asthma and AHR to mannitol received either 700 mg tezepelumab or placebo intravenously at 4-week intervals for 12 weeks. AHR to mannitol was assessed, and a bronchoscopy was performed at baseline and after 12 weeks. The primary outcome was the change in AHR from baseline to week-12 and secondary outcomes were changes in airway inflammation. Forty patients were randomised to receive either tezepelumab (n=20) or placebo (n=20). The mean change in PD15 with tezepelumab was 1.9 DD (95% CI 1.2 to 2.5) versus 1·0 (95% CI 0.3 to 1.6) with placebo; p=0.06. Nine (45%) tezepelumab and three (16%) placebo patients had a negative PD15 test at week-12, p=0.04. Airway tissue and BAL eosinophils decreased by 74% (95% CI -53 to -86) and 75% (95% CI -53 to -86) respectively with tezepelumab compared with an increase of 28% (95% CI -39 to 270) and a decrease of 7% (95% CI -49 to 72) respectively with placebo, p=0.004 and p=0.01. Inhibiting TSLP-signalling with tezepelumab reduced the proportion of patients with AHR and decreased eosinophilic inflammation in BAL and airway tissue.
1 May 2023 in American Journal of Respiratory and Critical Care Medicine
Rationale: Allergic asthma is linked to impaired bronchial epithelial secretion of IFNs, which may be causally linked to the increased risk of viral exacerbations. We have previously shown that allergen immunotherapy (AIT) effectively reduces asthma exacerbations and prevents respiratory infections requiring antibiotics; however, whether AIT alters antiviral immunity is still unknown. Objectives: To investigate the effect of house dust mite sublingual AIT (HDM-SLIT) on bronchial epithelial antiviral and inflammatory responses in patients with allergic asthma. Methods: In this double-blind, randomized controlled trial (VITAL [The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients with Allergic Asthma]), adult patients with HDM allergic asthma received HDM-SLIT 12-SQ or placebo for 24 weeks. Bronchoscopy was performed at baseline and at Week 24, which included sampling for human bronchial epithelial cells. Human bronchial epithelial cells were cultured at baseline and at Week 24 and stimulated with the viral mimic polyinosinic:polycytidylic acid (poly(I:C)). mRNA expression was quantified using qRT-PCR, and protein concentrations were measured using multiplex ELISA. Measurements and Main Results: Thirty-nine patients were randomized to HDM-SLIT (n = 20) or placebo (n = 19). HDM-SLIT resulted in increased polyinosinic:polycytidylic acid–induced expression of IFN-β at both the gene (P = 0.009) and protein (P = 0.02) levels. IFN-λ gene expression was also increased (P = 0.03), whereas IL-33 tended to be decreased (P = 0.09). On the other hand, proinflammatory cytokines IL-6 (P = 0.009) and TNF-α (tumor necrosis factor-α) (P = 0.08) increased compared with baseline in the HDM-SLIT group. There were no significant changes in TSLP (thymic stromal lymphopoietin), IL-4, IL-13, and IL-10. Conclusions: HDM-SLIT improves bronchial epithelial antiviral resistance to viral infection. These results potentially explain the efficacy of HDM-SLIT in reducing exacerbations in allergic asthma. Clinical trial registered with www.clinicaltrials.gov (NCT 04100902).
9 December 2023 in Journal of Allergy and Clinical Immunology
LALouise Munkholm Andreasson
Louise Munkholm Andreasson
GJGustav Ørting Jørgensen
+4
1 February 2017 in Respiratory Medicine
26 November 2011 in Expert Opinion on Pharmacotherapy
(2012). The use of inhaled mannitol in the diagnosis and management of asthma. Expert Opinion on Pharmacotherapy: Vol. 13, No. 1, pp. 115-123. doi: 10.1517/14656566.2012.638917
5 September 2021 in European Respiratory Journal
Background: Tezepelumab, an anti-TSLP mAb, reduces asthma exacerbations but the mechanisms remain unclear. Human bronchial epithelial cells (HBECs) are major producers of antiviral IFNβ as well as alarmins (TSLP and IL33) and Type2 (T2) cytokines that likely contribute to viral induced exacerbations. Aim: We hypothesized that tezepelumab therapy improves host tolerance to virus by decreasing inflammatory alarmins/cytokines without affecting anti-viral resistance. Methods: Bronchoalveolar lavage (BAL) and HBECs were obtained bronchoscopically from patients with uncontrolled asthma at baseline and after 12 weeks’ therapy with tezepelumab 700mg 4-weekly (n=13) or placebo (n=13) (NCT02698501). HBECs were cultured and exposed to viral infection mimic poly(I:C) or rhinovirus (RV) infection. Alarmins, cytokines and IFNβ were analysed by RTqPCR and multiplex ELISA. Results: IL33 was decreased in unstimulated HBECs in tezepelumab treated patients, correlating with lower IL33 gene expression in BAL (p<0.001 baseline vs post treatment). Tezepelumab also decreased IL33 expression when HBECs were stimulated with poly(I:C) or infected with RV (p<0.05). Poly(I:C) increased IL4 and IL13 release/expression from HBEC and this response was dampened by tezepelumab (p<0.05). This was not seen with poly(I:C)- or RV-induced IFNβ. Importantly, the alterations in cytokine expression were not seen in the placebo group. Conclusion: Blocking TSLP in uncontrolled asthma reduces epithelial IL33 as well as T2 cytokines in response to viral stimulation, whereas IFNβ is not affected. The data suggest that TSLP regulates host tolerance to virus which could explain in part the effect of tezepelumab on asthma exacerbations.